Overview
- The companies committed up to $1 billion over five years to a co-innovation lab in the San Francisco Bay Area, with a South San Francisco opening targeted for late March.
- The lab will use Nvidia’s Vera Rubin platform and the BioNeMo software stack to build biology foundation models from large, experimentally validated datasets.
- Executives said the goal is a continuous wet- and dry-lab loop that produces “ground truth” data to speed discovery and improve clinical development decisions.
- The collaboration extends across Lilly’s operations to areas such as manufacturing and commercial workflows, with automation efforts that include connecting instruments and robotics through partners like Thermo Fisher.
- Key details remain undisclosed, including the precise funding flows and procurement mechanics, and the firms plan to announce the site specifics in March.